EPIC STUDY NOW PUBLISHED!

(Evaluation of Pimobendan In Dogs With Cardiomegaly)

Discover the groundbreaking results of the largest veterinary cardiology trial in history.

READ THE FINDINGS HERE

THE OBJECTIVE

To study whether long-term administration of pimobendan to dogs with stage B2 mitral valve disease (MVD) will delay onset of clinical signs of congestive heart failure (CHF), cardiac-related death, or euthanasia (primary endpoint).

THE FINDINGS

Conclusive evidence of significant benefit achieved with administration of pimobendan in dogs with preclinical MVD:

infographic

The EPIC Study represents a giant leap forward in canine cardiology treatment.

READ THE FINDINGS HERE

Hear what the lead investigators are saying about the EPIC Study:

Adrian Boswood, MA, VetMB, DVC, DECVIM (Cardiology), MRCVS

Professor of Veterinary Cardiology,
Royal Veterinary College, University of London

Sonya Gordon, BSc, DVM, DVSc, DACVIM (Cardiology)

Associate Professor, Texas A&M College
of Veterinary Medicine & Biomedical Science

Jens Häggström, DVM PhD, DECVIM (Cardiology)

Professor of Internal Medicine, Swedish University of Agricultural
Sciences, Faculty of Veterinary Medicine and Animal Science

THE DESIGN

infographic

ACCESS TO THE FULL SITE IS AVAILABLE

For more information about the investigators, objectives, and execution of the EPIC Study, please continue reading through EPICTRIAL.COM.